Key result
Ellagic acid lowers systolic blood pressure by ~35 mmHg in hypertensive rats.
Why the study?
Does ellagic acid reduce blood pressure and oxidative stress in L-NAME-induced hypertensive rats?
Does ellagic acid reduce blood pressure and oxidative stress in L-NAME-induced hypertensive rats?
Ellagic acid mitigates L-NAME-induced hypertension in rats by restoring nitric oxide bioavailability and reducing oxidative stress.
Ellagic acid merits further preclinical study in hypertension; leaves open any human translation or clinical role.
The effect of ellagic acid on oxidative stress and hypertension induced by Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) was investigated. Male Sprague-Dawley rats were administrated with L-NAME (40 mg/kg/day) for five weeks. L-NAME induced high systolic blood pressure (SBP) and increased heart rate (HR), hindlimb vascular resistance (HVR) and oxidative stress. Concurrent treatment with ellagic acid (7.5 or 15 mg/kg) prevented these alterations. Co-treatment with ellagic acid was associated with up-regulation of endothelial nitric oxide synthase (eNOS) protein production and alleviation of oxidative stress as indicated by decreased superoxide production in the vascular tissue, reduced plasma malondialdehyde levels, reduced NADPH oxidase subunit p47phox expression and increased plasma nitrate/nitrite levels. Our results indicate that ellagic acid attenuates hypertension by reducing NADPH oxidase subunit p47phox expression, which prevents oxidative stress and restores NO bioavailability.
No takes yet. Share an insight, caveat, or question.
Berkban et al. (2015) studied L-NAME-induced hypertension (n=50). Ellagic acid vs. L-NAME (vehicle) was evaluated on Systolic blood pressure (SBP) (p=<0.05). Ellagic acid at 15 mg/kg/day significantly reduced systolic blood pressure compared to L-NAME alone (164.6 vs 199.4 mmHg, p<0.05) in a rat model of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: